Metabolon’s Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity
Metabolomics-Derived Pathway Scores Outperform Inflammatory Protein Markers—Delivering Risk Prediction Where Proteomics Falls…
MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer’s Disease
TAINAN, Feb. 10, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology…
Miltenyi Biotec Receives ‘Special Recognition Award’ for Pioneering Work in Cell & Gene Therapy at BioSpectrum India Excellence Awards 2025
NEW DELHI, Dec. 9, 2025 /PRNewswire/ -- Miltenyi Biotec has been honoured…
Xcell Biosciences and Culture Biosciences Partner to Advance Cell Therapy Quality Through AI and Machine Learning
SAN FRANCISCO, CALIFORNIA, UNITED STATES, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Xcell…
Vantive partners with IDBS to drive global digital transformation in vital organ therapy
WOKING, United Kingdom, Dec. 2, 2025 /PRNewswire/ -- IDBS, a Danaher company…
CQ Medical Expands Radiation Therapy Portfolio With Bionix Business Unit Acquisition
AVONDALE, Pa., Dec. 1, 2025 /PRNewswire/ -- CQ Medical, the global leader in…
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Natures Signal Transduction and Targeted Therapy
Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE,…
George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Associations Scientific Sessions 2025
London, UK, Boston, MA, 9 November 2025 – George Medicines, a late-stage…
Medera Presents Late-Breaking Data from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at American Heart Association Scientific Sessions 2025
November 09, 2025 09:00 ET | Source: Medera Inc. BOSTON, Nov. 09,…
Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa
DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive…
